References

• Allison, K. C., Chao, A. M., Bruzas, M. B., McCuen-Wurst, C., Jones, E., McAllister, C., Gruber, K., Berkowitz, R. I., Wadden, T. A., & Tronieri, J. S. (2022). A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obesity science & practice, 9(2), 127–136. https://doi.org/10.1002/osp4.619
• Bartel, S., McElroy, S. L., Levangie, D., & Keshen, A. (2024). Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. The International journal of eating disorders, 57(2), 286–293. https://doi.org/10.1002/eat.24109
• Mensinger, J. L., Cox, S. A., & Henretty, J. R. (2021). Treatment Outcomes and Trajectories of Change in Patients Attributing Their Eating Disorder Onset to Anti-obesity Messaging. Psychosomatic medicine, 83(7), 777–786. https://doi.org/10.1097/PSY.0000000000000962
• Nasrollahizadeh, A., Kheiri, G., Javankiani, S., Kheiri, S., Hamzavi, S. F., Karimi, M., Amini-Salehi, E., & Karimi, M. A. (2026). Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis. Diabetology & metabolic syndrome, 18(1), 29. https://doi.org/10.1186/s13098-025-02006-x
• Radkhah, H., Rahimipour Anaraki, S., Parhizkar Roudsari, P., Arabzadeh Bahri, R., Zooravar, D., Asgarian, S., Hosseini Dolama, R., Alirezaei, A., & Khalooeifard, R. (2025). The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. Eating and weight disorders : EWD, 30(1), 10. https://doi.org/10.1007/s40519-025-01720-9